These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 38729446)

  • 1. Relaxin as a treatment for musculoskeletal fibrosis: What we know and future directions.
    Nourmahnad A; Javad Shariyate M; Khak M; Grinstaff MW; Nazarian A; Rodriguez EK
    Biochem Pharmacol; 2024 Jul; 225():116273. PubMed ID: 38729446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism.
    Yuan S; Guo D; Liang X; Zhang L; Zhang Q; Xie D
    Front Cell Dev Biol; 2023; 11():1131481. PubMed ID: 37123405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimally invasive, sustained-release relaxin-2 microparticles reverse arthrofibrosis.
    Kirsch JR; Williamson AK; Yeritsyan D; Blessing WA; Momenzadeh K; Leach TR; Williamson PM; Korunes-Miller JT; DeAngelis JP; Zurakowski D; Nazarian RM; Rodriguez EK; Nazarian A; Grinstaff MW
    Sci Transl Med; 2022 Oct; 14(666):eabo3357. PubMed ID: 36223449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Recombinant Relaxin (Serelaxin) as Anti-fibrotic Agent: Pharmacology, Limitations and Actual Perspectives.
    Sassoli C; Nistri S; Chellini F; Bani D
    Curr Mol Med; 2022; 22(3):196-208. PubMed ID: 33687895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directions.
    Samuel CS; Bennett RG
    Biochem Pharmacol; 2022 Mar; 197():114884. PubMed ID: 34968489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relaxin and fibrosis: Emerging targets, challenges, and future directions.
    Kanai AJ; Konieczko EM; Bennett RG; Samuel CS; Royce SG
    Mol Cell Endocrinol; 2019 May; 487():66-74. PubMed ID: 30772373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relaxin-Loaded Inhaled Porous Microspheres Inhibit Idiopathic Pulmonary Fibrosis and Improve Pulmonary Function Post-Bleomycin Challenges.
    Qiu S; Fu X; Shi Y; Zang H; Zhao Y; Qin Z; Lin G; Zhao X
    Mol Pharm; 2023 Aug; 20(8):3947-3959. PubMed ID: 37358639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of relaxin on extracellular matrix remodeling in health and fibrotic disease.
    Samuel CS; Lekgabe ED; Mookerjee I
    Adv Exp Med Biol; 2007; 612():88-103. PubMed ID: 18161483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis.
    Hewitson TD; Mookerjee I; Masterson R; Zhao C; Tregear GW; Becker GJ; Samuel CS
    Endocrinology; 2007 Feb; 148(2):660-9. PubMed ID: 17095590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-fibrotic actions of relaxin.
    Samuel CS; Royce SG; Hewitson TD; Denton KM; Cooney TE; Bennett RG
    Br J Pharmacol; 2017 May; 174(10):962-976. PubMed ID: 27250825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relaxin in hepatic fibrosis: What is known and where to head?
    Ezhilarasan D
    Biochimie; 2021 Aug; 187():144-151. PubMed ID: 34102254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate.
    Wang C; Kemp-Harper BK; Kocan M; Ang SY; Hewitson TD; Samuel CS
    Front Pharmacol; 2016; 7():91. PubMed ID: 27065874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relaxin abrogates genomic remodeling of the aged heart.
    Romero G; Salama G
    Vitam Horm; 2021; 115():419-448. PubMed ID: 33706957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relaxin-expressing adenovirus decreases collagen synthesis and up-regulates matrix metalloproteinase expression in keloid fibroblasts: in vitro experiments.
    Lee WJ; Choi IK; Lee JH; Lee JS; Kim YO; Rah DK; Yun CO
    Plast Reconstr Surg; 2012 Sep; 130(3):407e-417e. PubMed ID: 22929264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-fibrotic actions of relaxin are mediated through AT
    Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
    FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relaxin Inhibits the Cardiac Myofibroblast NLRP3 Inflammasome as Part of Its Anti-Fibrotic Actions via the Angiotensin Type 2 and ATP (P2X7) Receptors.
    Tapia Cáceres F; Gaspari TA; Hossain MA; Samuel CS
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relaxin Ameliorates Renal Fibrosis and Expression of Endothelial Cell Transition Markers in Rats of Isoproterenol-Induced Heart Failure.
    Zheng G; Cai J; Chen X; Chen L; Ge W; Zhou X; Zhou H
    Biol Pharm Bull; 2017; 40(7):960-966. PubMed ID: 28674260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-β/Smad3 signaling.
    Sassoli C; Chellini F; Pini A; Tani A; Nistri S; Nosi D; Zecchi-Orlandini S; Bani D; Formigli L
    PLoS One; 2013; 8(5):e63896. PubMed ID: 23704950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotective actions of relaxin.
    Martin B; Romero G; Salama G
    Mol Cell Endocrinol; 2019 May; 487():45-53. PubMed ID: 30625345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relaxin decreases the severity of established hepatic fibrosis in mice.
    Bennett RG; Heimann DG; Singh S; Simpson RL; Tuma DJ
    Liver Int; 2014 Mar; 34(3):416-26. PubMed ID: 23870027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.